772 related articles for article (PubMed ID: 11112383)
1. Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece.
Loukopoulos D; Voskaridou E; Kalotychou V; Schina M; Loutradi A; Theodoropoulos I
Blood Cells Mol Dis; 2000 Oct; 26(5):453-66. PubMed ID: 11112383
[TBL] [Abstract][Full Text] [Related]
2. Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease.
Rodgers GP; Dover GJ; Uyesaka N; Noguchi CT; Schechter AN; Nienhuis AW
N Engl J Med; 1993 Jan; 328(2):73-80. PubMed ID: 7677965
[TBL] [Abstract][Full Text] [Related]
3. Hydroxyurea in sickle cell disease--a study of clinico-pharmacological efficacy in the Indian haplotype.
Italia K; Jain D; Gattani S; Jijina F; Nadkarni A; Sawant P; Nair S; Mohanty D; Ghosh K; Colah R
Blood Cells Mol Dis; 2009; 42(1):25-31. PubMed ID: 18954999
[TBL] [Abstract][Full Text] [Related]
4. Pharmacologic manipulation of fetal hemoglobin levels in sickle cell diseases and thalassemia: promise and reality.
Pearson HA
Adv Pediatr; 1996; 43():309-34. PubMed ID: 8794181
[No Abstract] [Full Text] [Related]
5. Overview of pathophysiology and rationale for treatment of sickle cell anemia.
Rodgers GP
Semin Hematol; 1997 Jul; 34(3 Suppl 3):2-7. PubMed ID: 9317195
[TBL] [Abstract][Full Text] [Related]
6. Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea.
Rodgers GP; Dover GJ; Noguchi CT; Schechter AN; Nienhuis AW
N Engl J Med; 1990 Apr; 322(15):1037-45. PubMed ID: 1690857
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults.
Charache S
Semin Hematol; 1997 Jul; 34(3 Suppl 3):15-21. PubMed ID: 9317197
[TBL] [Abstract][Full Text] [Related]
8. The presence of alpha-thalassaemia trait blunts the response to hydroxycarbamide in patients with sickle cell disease.
Vasavda N; Badiger S; Rees D; Height S; Howard J; Thein SL
Br J Haematol; 2008 Nov; 143(4):589-92. PubMed ID: 18764867
[TBL] [Abstract][Full Text] [Related]
9. Hydroxyurea in sickle cell disease patients from Eastern Saudi Arabia.
Al-Jam'a AH; Al-Dabbous IA
Saudi Med J; 2002 Mar; 23(3):277-81. PubMed ID: 11938415
[TBL] [Abstract][Full Text] [Related]
10. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia.
Ballas SK; McCarthy WF; Guo N; Brugnara C; Kling G; Bauserman RL; Waclawiw MA
Hemoglobin; 2010; 34(5):424-9. PubMed ID: 20854115
[TBL] [Abstract][Full Text] [Related]
11. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP
Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
[TBL] [Abstract][Full Text] [Related]
12. A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders.
Perrine SP; Ginder GD; Faller DV; Dover GH; Ikuta T; Witkowska HE; Cai SP; Vichinsky EP; Olivieri NF
N Engl J Med; 1993 Jan; 328(2):81-6. PubMed ID: 7677966
[TBL] [Abstract][Full Text] [Related]
13. Effects of hydroxyurea on the membrane of erythrocytes and platelets in sickle cell anemia.
Covas DT; de Lucena Angulo I; Vianna Bonini Palma P; Zago MA
Haematologica; 2004 Mar; 89(3):273-80. PubMed ID: 15020264
[TBL] [Abstract][Full Text] [Related]
14. The effect of hydroxyurea on the coagulation system in sickle cell anemia and beta-thalassemia intermedia patients: a preliminary study.
Koc A; Gumruk F; Gurgey A
Pediatr Hematol Oncol; 2003 Sep; 20(6):429-34. PubMed ID: 14631615
[TBL] [Abstract][Full Text] [Related]
15. Use of hydroxyurea in children with sickle cell disease: what comes next?
Ohene-Frempong K; Smith-Whitley K
Semin Hematol; 1997 Jul; 34(3 Suppl 3):30-41. PubMed ID: 9317199
[TBL] [Abstract][Full Text] [Related]
16. Concordant fetal hemoglobin response to hydroxyurea in siblings with sickle cell disease.
Steinberg MH; Voskaridou E; Kutlar A; Loukopoulos D; Koshy M; Ballas SK; Castro O; Barton F
Am J Hematol; 2003 Feb; 72(2):121-6. PubMed ID: 12555216
[TBL] [Abstract][Full Text] [Related]
17. Spectrum of fetal hemoglobin responses in sickle cell patients treated with hydroxyurea: the National Institutes of Health experience.
Rodgers GP
Semin Oncol; 1992 Jun; 19(3 Suppl 9):67-73. PubMed ID: 1379375
[TBL] [Abstract][Full Text] [Related]
18. Cerebrovascular events in sickle cell-beta thalassemia treated with hydroxyurea: a single center prospective survey in adult Italians.
Rigano P; Pecoraro A; Calvaruso G; Steinberg MH; Iannello S; Maggio A
Am J Hematol; 2013 Nov; 88(11):E261-4. PubMed ID: 23828131
[TBL] [Abstract][Full Text] [Related]
19. Effects of hydroxyurea in a population of Brazilian patients with sickle cell anemia.
Vicari P; Barretto de Mello A; Figueiredo MS
Am J Hematol; 2005 Mar; 78(3):243-4. PubMed ID: 15726590
[TBL] [Abstract][Full Text] [Related]
20. Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia.
Di Maggio R; Hsieh MM; Zhao X; Calvaruso G; Rigano P; Renda D; Tisdale JF; Maggio A
Int J Mol Sci; 2018 Feb; 19(3):. PubMed ID: 29495591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]